silver
Overview
Silver (Ag, atomic number 47) is a precious transition metal with a rich history of antimicrobial and therapeutic applications in medicine. Beyond its traditional use in wound dressings and surface coatings, silver has emerged as a critical component in modern nanomedicine, particularly in the form of silver nanoparticles (AgNPs). These nanoparticles exhibit enhanced bioactivity compared to bulk silver, owing to their high surface area-to-volume ratio and quantum-size effects. Contemporary research has focused on exploiting silver's antimicrobial, antioxidant, and anti-inflammatory properties through rational nanoparticle synthesis and strategic conjugation with bioactive compounds. The versatility of silver in therapeutic nanotechnology has positioned it as a key platform for developing multifunctional nanomedicines targeting infectious diseases, inflammatory conditions, and malignant tumors.
Recent Publications Summary
Recent studies on silver focused largely on nanoparticle-based platforms for wound care, antimicrobial therapy, and cancer treatment. In chronic wound management, a silver-curcumin hydrocolloid dressing was developed as a mechanically robust and moisture-retentive dressing, with characterized silver nanoparticles showing stable formation, a hydrodynamic size of 197.3 ± 0.709 nm, and a zeta potential of -27.5 ± 0.603 mV; the final dressing demonstrated a porous structure, uniform nanoparticle distribution, superior tensile strength, and a swelling ratio of 428.76%, exceeding commercial dressings 42586992Aug. In a canine full-thickness wound model, chitosan-capped silver nanoparticles combined with platelet-rich plasma produced the greatest wound size reduction and contraction over 21 days, with associated assessments of histopathology, collagen deposition, and immunohistochemical markers including epidermal growth factor and α-SMA 42484703Jul.
Several publications examined biosynthesized silver nanoparticles with antimicrobial and bioactive properties. Famotidine-conjugated green silver nanoparticles were reported to form a stable ~6 nm core and to selectively inhibit gastric and prostate cancer cells while sparing healthy human dermal fibroblasts, with strong antibacterial activity against Bacillus cereus and measurable DPPH antioxidant activity 42361624Jun. Silver nanoparticles synthesized using Falconeria insignis Royle leaf extract showed a surface plasmon resonance peak at 300–350 nm, nanocrystalline silver with a mean crystallite size of 19 nm, and higher antibacterial activity against Staphylococcus aureus than crude extract or silver nitrate 42340945Jun. Fungal-mediated silver nanoparticles from Porostereum spadiceum were also characterized as smooth, spherical, and crystalline, and were reported to enhance in vitro and in vivo antidiabetic, antioxidant, and anti-inflammatory activities compared with the extract alone 42097278May.
Other studies explored silver in hybrid therapeutic systems for inflammation and cancer. A silver nanoparticle-conjugated BN6 pyrimidine derivative was tested in a dextran sulfate sodium-induced inflammatory bowel disease zebrafish model, where drug release, entrapment efficiency, inflammatory markers, oxidative stress, and cellular damage were evaluated; the abstract indicates that the conjugate was designed to improve anti-inflammatory, antioxidant, and drug-delivery performance 42116596May. In triple-negative breast cancer, a silver-selenium hybrid nanocomposite built on a mesoporous silica platform and functionalized with transferrin showed selective internalization, enhanced cytotoxicity, G0/G1 arrest, and strong apoptosis induction in MDA-MB-231 cells 41833246Mar. Silver was also included as one component of a gold-bismuth-platinum-silver-palladium high-entropy alloy used in a radioimmunotherapy sensitization platform for lung metastases 41914367Mar.
What Changes, What Holds
1. Silver is being pushed from broad antimicrobial dressing material toward more engineered wound-repair platforms
REINFORCES Silver-based wound care remains the main line of development, but the new dressing and the canine combination study mainly sharpen the therapeutic proposition rather than changing it. They support the existing view that silver nanoparticles can be integrated into advanced dressings and regenerative regimens to improve moisture handling, mechanics, and healing-related outcomes. No baseline claim is overturned; the work extends practical formulation and combination strategies for wound management 42586992Aug42484703Jul.
2. Biosynthesized silver nanoparticles keep confirming antimicrobial, antioxidant, and anticancer activity while underscoring that effects depend on formulation
REINFORCES Green and fungal synthesis approaches continue to strengthen the established account of silver as a multifunctional nanomedicine platform, not a new role. What changes is the specificity of the chemistry: stability, nanoscale size, and biological selectivity are being tied more tightly to activity against bacteria, cancer cells, and oxidative stress. The mixed bioactivity profile also suggests that source and conjugation matter for efficacy and safety, but this is still an extension of the baseline 42361624Jun42340945Jun42097278May.
3. Silver is expanding into hybrid drug-delivery and cancer-sensitization systems rather than only acting as a stand-alone antimicrobial
NEW DIRECTION Silver’s established antimicrobial and wound-care role is left intact, but these studies place it in roles the Overview does not yet cover: as part of inflammation-targeted release systems, a transferrin-guided cytotoxic nanocomposite, and a component of a sensitization alloy for metastasis therapy. That broadens silver from direct bioactivity to platform engineering for delivery and combination treatment. The evidence is preclinical, so these are promising directions rather than settled clinical uses 42116596May41833246Mar41914367Mar.
Overview update candidates: hybrid anti-inflammatory drug delivery; targeted cancer nanocomposites; and radioimmunotherapy sensitization platforms using silver as a component.
silver
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding silver are described as follows:
- infection (Disease) — 4 papers: PMIDs 42586992, 42484703, 42483953, 42423026
- Bacterial infection (Disease) — 2 papers: PMIDs 42543002, 42349732
- diabetes mellitus (Disease) — 2 papers: PMIDs 42423026, 42097278
- inflammation (Biological Process) — 2 papers: PMIDs 42483953, 42116596
- reactive oxygen species (Chemical) — 2 papers: PMIDs 42349732, 41914367
- wound healing (Clinical Metric) — 2 papers: PMIDs 42543002, 42484703
- (+)-thioctic acid (Chemical) — 1 paper: PMIDs 42423007
- antibiotic resistance (Biological Process) — 1 paper: PMIDs 42543002
- Antibiotics (Chemical) — 1 paper: PMIDs 42543002
- cancer nanomedicine (Disease) — 1 paper: PMIDs 41809385
- cardiovascular disease (Disease) — 1 paper: PMIDs 42069266
- cellular regeneration (Biological Process) — 1 paper: PMIDs 42543002
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study silver:
- DPPH (Other) — 2 papers: PMIDs 42361624, 42097278
- energy-dispersive X-ray spectroscopy (Technology) — 2 papers: PMIDs 42586992, 42097278
- epidermal growth factor (Protein) — 2 papers: PMIDs 42484703, 42483953
- Gold (Chemical) — 2 papers: PMIDs 42290459, 41779332
- hydrogel (Other) — 2 papers: PMIDs 42423026, 42349732
- polyvinyl alcohol (Chemical) — 2 papers: PMIDs 42423026, 42349732
- Scanning Electron Microscopy (Technology) — 2 papers: PMIDs 42586992, 42097278
- silver nanoparticle (Technology) — 2 papers: PMIDs 42116596, 42097278
- Actin gamma 2, smooth muscle (Protein) — 1 paper: PMIDs 42484703
- adolescence (Chemical) — 1 paper: PMIDs 42530666
- AI/machine learning (Technology) — 1 paper: PMIDs 42290459
- alloxan (Chemical) — 1 paper: PMIDs 42097278
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to silver include:
- Gold (Chemical) — 2 papers: PMIDs 42069266, 41914367
- (Z)-N-(4-(2-chlorophenyl)-6-(4-nitrophenyl)pyrimidin-2-yl)-1-(furan-2-yl)methanimine (Chemical) — 1 paper: PMIDs 42116596
- 2-phenylchromane flavonoid (Chemical) — 1 paper: PMIDs 42340945
- Acid α-glucosidase (AAG) (Protein) — 1 paper: PMIDs 42097278
- Ag@MSN-Tf-SeNPs (Other) — 1 paper: PMIDs 41833246
- amylase (Protein) — 1 paper: PMIDs 42097278
- bismuth (Chemical) — 1 paper: PMIDs 41914367
- cell cycle (Biological Process) — 1 paper: PMIDs 41914367
- chitosan (Chemical) — 1 paper: PMIDs 42484703
- crystalline silica (Chemical) — 1 paper: PMIDs 42069266
- curcumin (Chemical) — 1 paper: PMIDs 42586992
- famotidine (Therapy) — 1 paper: PMIDs 42361624
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with silver include:
- inflammation (Biological Process) — 3 papers: PMIDs 42586992, 42423026, 42423007
- tumor necrosis factor‑α (Protein) — 3 papers: PMIDs 42586992, 42349732, 42116596
- angiogenesis (Biological Process) — 2 papers: PMIDs 42423026, 42423007
- cell viability (Clinical Metric) — 2 papers: PMIDs 42543002, 42530666
- collagen deposition (Clinical Metric) — 2 papers: PMIDs 42484703, 42483953
- Escherichia coli (Organism) — 2 papers: PMIDs 42586992, 42483953
- Interleukin 1 beta (Protein) — 2 papers: PMIDs 42586992, 42116596
- methicillin-resistant Staphylococcus aureus (Organism) — 2 papers: PMIDs 42586992, 42483953
- minimum inhibitory concentration (Clinical Metric) — 2 papers: PMIDs 42530666, 42361624
- oxidative stress (Biological Process) — 2 papers: PMIDs 42586992, 42543002
- Staphylococcus aureus (Organism) — 2 papers: PMIDs 42586992, 42481379
- temperature (Other) — 2 papers: PMIDs 42481379, 42069266
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding silver are summarized below:
- oxidative stress (Biological Process) — 2 papers: PMIDs 42349732, 42097278
- abscopal immune effect (Biological Process) — 1 paper: PMIDs 41914367
- Acceptable safety (Clinical Metric) — 1 paper: PMIDs 42530666
- Acidic Environment (Other) — 1 paper: PMIDs 42423007
- advanced wound management (Other) — 1 paper: PMIDs 42543002
- Alkaline Environment (Other) — 1 paper: PMIDs 42423007
- bio-medical interventions (Other) — 1 paper: PMIDs 42069266
- biocompatible antioxidant-rich carriers (Other) — 1 paper: PMIDs 41779332
- biomedical antibacterial uses (Other) — 1 paper: PMIDs 42340945
- body fluid (Other) — 1 paper: PMIDs 42290459
- cardiovascular therapy (Therapy) — 1 paper: PMIDs 42069266
- chitosan (Chemical) — 1 paper: PMIDs 42484703
